Platform / Diagnostics

See more in a single sample.

When standard tools can’t see CNS cancer, the answer is in the cerebrospinal fluid (CSF). Cerenome’s diagnostics detect and characterize disease from a single CSF sample, bringing cellular and molecular detail where there was almost none.

Why It Matters

Why standard tools fall short.

Finding CNS cancers early, and following them through treatment, is only as effective as the tools available. CSF cytology has limited sensitivity and often requires repeat patient sample collections to detect disease. Standard imaging can’t resolve disease at the cellular or molecular level. And neither is repeatable enough to track how the disease responds over time. A CSF-based cellular and molecular assay is built to close those gaps.

1. Hajdu SI, Ehya H. Foundation of diagnostic cytology. Ann Clin Lab Sci. 2008;38(3):296-299.

CSF cytology, still the standard test, was introduced in 1904.1

Concentric rings from 1904 at the centre to 2026 at the edge.

How It Works

Painting a molecular picture.

From a single cerebrospinal fluid sample, CNSide® quantifies tumor cells and characterizes them at the cellular and molecular level. Because the sample is minimally invasive to obtain and can be repeated, the same assay works at diagnosis and throughout treatment, to see whether the disease is responding to treatment.

Through a collaboration with Genomic Testing Cooperative, that molecular profile has expanded to include DNA and RNA sequencing across hundreds of clinically relevant biomarkers from the same sample.

For clinicians, that means:

A test to reach for when leptomeningeal metastases are suspected but CSF cytology is inconclusive.

A readout of tumor-cell burden and biomarkers when results return.

A way to follow that burden over time as treatment decisions are made.

Man in glasses and a navy vest speaking during an interview in a bright, modern lounge.

Where the system starts.

Hear from the President and General Manager of CNSide® Diagnostics on the gap CNSide® fills, how the assay works, and how its results feed the therapeutics and data sides of the platform.

Better as part of the system.

Within the platform, diagnostics both give and gain. Each CSF characterization informs treatment and tracks response, feeding the data layer. In return, that data layer is designed to learn across cases, refining what the assay looks for and how its results are read, so detection improves as the system does.

Trusted by physicians.

For a clinician deciding whether to order a test, access matters as much as evidence. CNSide® has both.

CSF analysis is increasingly central to how CNS cancers are diagnosed and monitored.

The updated NCCN Central Nervous System Cancers Guidelines now include CSF circulating tumor cells alongside tumor-derived DNA.1

The leptomeningeal diagnostic framework broadens from CSF cytology alone to CSF analysis, the testing CNSide®* performs.

Reimbursement and access are increasingly central to whether a diagnostic actually reaches patients.

CNSide® is CLIA-licensed, CAP-accredited, and available to order in all 50 states.

It carries a unique PLA code for billing and is enrolled with Medicare, with contracted coverage across approximately 190 million covered lives.†

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Central Nervous System Cancers. Version 2.2026.

*CNSide® is a laboratory-developed test. It has not been cleared or approved by the FDA.

†Coverage depends on test type, each plan’s medical policy, and the member’s benefits.

Gloved hands holding a test tube of blue liquid in a lab setting.

Actor portrayal

CNSide logo

CNSide®, the platform behind our diagnostics.

CNSide® is the CSF assay platform that powers Cerenome’s diagnostics capability. From a single spinal-fluid sample, it’s designed to detect and quantify tumor cells that standard tests can miss.